Page last updated: 2024-09-03

marimastat and pd168393

marimastat has been researched along with pd168393 in 1 studies

Compound Research Comparison

Studies
(marimastat)
Trials
(marimastat)
Recent Studies (post-2010)
(marimastat)
Studies
(pd168393)
Trials
(pd168393)
Recent Studies (post-2010) (pd168393)
215285361033

Protein Interaction Comparison

ProteinTaxonomymarimastat (IC50)pd168393 (IC50)
Proto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)1.0702
Epidermal growth factor receptorHomo sapiens (human)0.0143
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.0334
Tyrosine-protein kinase FynHomo sapiens (human)0.1543
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.073
Receptor tyrosine-protein kinase erbB-3Homo sapiens (human)0.0011
Tyrosine-protein kinase BlkHomo sapiens (human)5.47
Cytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)0.5757
Tyrosine-protein kinase JAK3Homo sapiens (human)3.14
Tyrosine-protein kinase BTKHomo sapiens (human)5.83
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)0.0047

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cartee, TV; Pollack, BP; Sapkota, B1

Other Studies

1 other study(ies) available for marimastat and pd168393

ArticleYear
Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jul-01, Volume: 17, Issue:13

    Topics: Antibodies, Blocking; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Line; Cell Line, Tumor; Cetuximab; ErbB Receptors; Gene Expression Regulation; HCT116 Cells; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; HLA-DR Antigens; Humans; Hydroxamic Acids; Immunologic Factors; Interferon-gamma; Keratinocytes; Models, Biological; Nuclear Proteins; Protein Kinase Inhibitors; Quinazolines; Skin; Trans-Activators

2011